Leisure Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Leisure Capital Management’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-145	Closed	-$5K	–	137
2018 Q4	$5K	Sell	145 -13	-8%	-$941	﹤0.01%	126
2018 Q3	$12K	Buy	+158	New	+$11.9K	0.01%	129
2018 Q2	–	Sell	-161	Closed	-$14K	–	144
2018 Q1	$14K	Sell	161 -3	-2%	-$446	0.01%	143
2017 Q4	$122K	Buy	164 +4	+3%	+$1.54K	0.1%	110
2017 Q3	$46K	Sell	160 -3	-2%	-$819	0.04%	106
2017 Q2	$42K	Sell	163 -5	-3%	-$1.34K	0.04%	110
2017 Q1	$56K	Sell	168 -5	-3%	-$2.32K	0.05%	104
2016 Q4	$104K	Buy	173 +3	+2%	+$3.17K	0.09%	103
2016 Q3	$192K	Sell	170 -1	-0.6%	-$1.08K	0.18%	93
2016 Q2	$187K	Hold	171	–	–	0.18%	92
2016 Q1	$219K	Hold	171	–	–	0.22%	83
2015 Q4	$419K	Buy	171 +5	+3%	+$7.67K	0.38%	65
2015 Q3	$184K	Buy	166 +5	+3%	+$5.79K	0.2%	80
2015 Q2	$162K	Buy	161 +9	+6%	+$9.71K	0.16%	86
2015 Q1	$154K	Buy	+152	New	+$502K	0.15%	85

Other funds holding NBSE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIG

Mariner Investment Group Harrison, New York $346M AUM 25.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SSB

Sandy Spring Bank Olney, Maryland $2.38B AUM 8.14% 1-Year Est. Return

WAM

Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return

Leisure Capital Management's NBSE Position: Q1 2019 in Review

Leisure Capital Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2019, closing a stake of 145 shares — an estimated $5K sold.

Leisure Capital Management first reported a position in NBSE in Q1 2015 and held it in 15 quarters. The position peaked at $419K in Q4 2015. 15 funds tracked by Wall St. Rank hold NBSE as of Q1 2019.

Leisure Capital Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Leisure Capital Management sold 145 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $5K.
Leisure Capital Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2015 and held it in 15 quarters.
Leisure Capital Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $419K in Q4 2015.
15 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Leisure Capital Management's 13F filing for Q1 2019, filed 8 May 2019.